Oridonin inhibits IL-1β-induced inflammation in human osteoarthritis chondrocytes by activating PPAR-γ

Area of Science:

• Biochemistry
• Pharmacology
• Rheumatology

Background:

• Osteoarthritis (OA) is a prevalent degenerative joint disease affecting millions globally.
• Inflammation, driven by factors like Interleukin-1 beta (IL-1β), plays a critical role in OA pathogenesis.
• Current treatments for OA focus on symptom management, highlighting the need for disease-modifying agents.

Purpose of the Study:

• To investigate the anti-inflammatory effects of oridonin, a diterpenoid from Rabdosia rubescens.
• To evaluate oridonin's impact on IL-1β-induced inflammatory responses in human osteoarthritis chondrocytes.
• To explore the molecular mechanisms underlying oridonin's potential therapeutic action in OA.

Main Methods:

• Human osteoarthritis chondrocytes were treated with IL-1β and varying concentrations of oridonin.
• Analysis included measuring the production of matrix metalloproteinases (MMPs), nitric oxide (NO), and prostaglandin E2 (PGE2).
• Western blot was used to assess the expression of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), NF-κB activation, and PPAR-γ.

Main Results:

• Oridonin significantly suppressed IL-1β-induced production of MMP1, MMP3, and MMP13.
• Oridonin attenuated IL-1β-induced NO and PGE2 production, and reduced iNOS and COX-2 expression.
• Oridonin inhibited NF-κB activation and dose-dependently increased PPAR-γ expression; a PPAR-γ antagonist reversed these anti-inflammatory effects.

Conclusions:

• Oridonin exhibits potent anti-inflammatory properties against IL-1β-induced responses in osteoarthritis chondrocytes.
• The anti-inflammatory effects of oridonin are mediated, at least in part, through the modulation of NF-κB and PPAR-γ pathways.
• Oridonin demonstrates potential as a novel therapeutic candidate for managing osteoarthritis.